- International families
- 40k2015 to 2024
- Leading country
- United States3.3× the next
- All families
- 144khome filings included
- Over five years
- Rising2020 to 2024 against the five before
Year by year
Patent families by country of origin and the year of the earliest filing, 2000 to 2025; 2025 is a part year, still filling in. International families are those for which protection was sought beyond one country.
Volume
International patent families in the capability, by the year of the earliest filing.
Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google
Share by country
Each country's share of the year's international families, in per cent: the capability's five largest countries of origin, 2015 to 2024, and the rest of the world.
Source: Global Institute for National Capability (GINC), 2026. Underlying patents from 107 patent offices, IFI CLAIMS and Google
Country leaderboard
International patent families, 2015 to 2024, by country of origin. Growth compares the latest five full years with the five before.
Ten largest
United States
China
Japan
South Korea
Germany
United Kingdom
France
Switzerland
Netherlands
Canada
17,818
5,444
3,003
2,851
1,616
1,376
1,081
809
605
592
| 2000 to 2025 | ||||||
|---|---|---|---|---|---|---|
| 1 | United States | 17,818 | 44.8% | 1.1× | 22,138 | |
| 2 | China | 5,444 | 13.7% | 2.3× | 92,611 | |
| 3 | Japan | 3,003 | 7.5% | 0.9× | 5,085 | |
| 4 | South Korea | 2,851 | 7.2% | 1.4× | 10,200 | |
| 5 | Germany | 1,616 | 4.1% | 1.1× | 1,770 | |
| 6 | United Kingdom | 1,376 | 3.5% | 1.0× | 1,518 | |
| 7 | France | 1,081 | 2.7% | 1.0× | 1,160 | |
| 8 | Switzerland | 809 | 2.0% | 1.0× | 886 | |
| 9 | Netherlands | 605 | 1.5% | 1.1× | 743 | |
| 10 | Canada | 592 | 1.5% | 0.8× | 701 | |
| 11 | Israel | 459 | 1.2% | 1.3× | 490 | |
| 12 | Taiwan | 438 | 1.1% | 1.0× | 838 | |
| 13 | Spain | 438 | 1.1% | 1.2× | 513 | |
| 14 | Singapore | 358 | 0.9% | 1.3× | 380 | |
| 15 | Australia | 350 | 0.9% | 0.9× | 384 | |
| 16 | Belgium | 308 | 0.8% | 1.0× | 331 | |
| 17 | Italy | 255 | 0.6% | 1.2× | 322 | |
| 18 | Sweden | 254 | 0.6% | 1.5× | 264 | |
| 19 | India | 230 | 0.6% | 1.2× | 300 | |
| 20 | Denmark | 157 | 0.4% | 0.9× | 168 | |
| 21 | Türkiye | 114 | 0.3% | 2.5× | 179 | |
| 22 | Austria | 103 | 0.3% | 0.9× | 107 | |
| 23 | Poland | 102 | 0.3% | 1.4× | 343 | |
| 24 | Norway | 86 | 0.2% | 0.9× | 92 | |
| 25 | Ireland | 72 | 0.2% | 1.5× | 91 | |
| 26 | Finland | 66 | 0.2% | 1.3× | 73 | |
| 27 | Russia | 66 | 0.2% | 0.6× | 899 | |
| 28 | Hong Kong | 61 | 0.2% | 2.4× | 90 | |
| 29 | Brazil | 59 | 0.1% | 1.5× | 200 | |
| 30 | Cayman Islands | 52 | 0.1% | 0.2× | 55 | |
| 31 | Portugal | 50 | 0.1% | 1.9× | 62 | |
| 32 | New Zealand | 43 | 0.1% | 0.7× | 48 | |
| 33 | Saudi Arabia | 35 | 0.1% | 0.7× | 61 | |
| 34 | Czechia | 30 | 0.1% | 1.7× | 75 | |
| 35 | Hungary | 28 | 0.1% | 1.2× | 40 | |
| 36 | Malaysia | 22 | 0.1% | 0.3× | 63 | |
| 37 | Mexico | 20 | 0.1% | 0.8× | 106 | |
| 38 | South Africa | 15 | 0.0% | 0.9× | 16 | |
| 39 | Luxembourg | 13 | 0.0% | 0.4× | 18 |
Applicants
The largest applicants by international patent families, 2015 to 2024: across the world, then within each of the five countries with the most families in Genomics & Biological Data. Names are as held in the source and are not consolidated across subsidiaries.
Global
39,800 international families
ILLUMINA INC · United States
UNIV CALIFORNIA · United States
PIONEER HI BRED INT · United States
HOFFMANN LA ROCHE · Switzerland
INST NAT SANTE RECH MED · France
UNIV LELAND STANFORD JUNIOR · United States
784
647
495
482
351
318
United States
17,818 international families
ILLUMINA INC
UNIV CALIFORNIA
PIONEER HI BRED INT
UNIV LELAND STANFORD JUNIOR
HARVARD COLLEGE
MASSACHUSETTS INST TECHNOLOGY
770
627
493
311
296
288
China
5,444 international families
BGI SHENZHEN
MGI TECH CO LTD
SHENZHEN BGI LIFE SCIENCE RES INSTITUTE
BOE TECHNOLOGY GROUP CO LTD
BGI SHENZHEN CO LTD
SHENZHEN INST OF ADV TECH CAS
267
186
155
104
91
77
Japan
3,003 international families
UNIV TOKYO
FUJIFILM CORP
HITACHI HIGH TECH CORP
SYSMEX CORP
SHIMADZU CORP
UNIV OSAKA
122
109
103
101
86
85
South Korea
2,851 international families
SEOUL NAT UNIV R&DB FOUNDATION
SEEGENE INC
UNIV YONSEI IACF
UNIV KOREA RES & BUS FOUND
UNIV ULSAN FOUND IND COOP
ASAN FOUND
160
129
126
105
94
92
Germany
1,616 international families
BOSCH GMBH ROBERT
QIAGEN GMBH
IMMATICS BIOTECHNOLOGIES GMBH
LEICA MICROSYSTEMS
KWS SAAT SE & CO KGAA
MILTENYI BIOTEC BV & CO KG
101
76
56
48
44
42
Similar capabilities
The nine capabilities that share the most international patent families with Genomics & Biological Data, 2015 to 2024: the families counted in both as a share of those counted in either. Each card shows its five largest countries.
Critical Technology
Synthetic Biology & Genetic Engineering
14.7% shared · 14,676 families in both
United States
China
Japan
South Korea
Germany
31,378
14,103
6,820
3,970
2,703
Human Capital
Public Health Functions
12.4% shared · 5,959 families in both
United States
China
Japan
South Korea
Germany
5,511
1,782
1,627
909
600
Strategic Infrastructure
Public Health & Laboratories
10.5% shared · 5,823 families in both
United States
Japan
China
Germany
South Korea
7,163
3,632
2,667
1,475
1,202
Critical Technology
Biomanufacturing
8.1% shared · 8,295 families in both
United States
China
Japan
South Korea
Germany
25,142
10,048
9,595
4,747
3,497
Critical Technology
Advanced Therapeutics, Vaccines & Medical Countermeasures
5.2% shared · 5,758 families in both
United States
China
Japan
South Korea
Germany
35,382
11,223
4,471
4,072
2,767
Human Capital
Knowledge Production
4.3% shared · 3,059 families in both
United States
Japan
Germany
China
South Korea
9,688
6,387
4,131
2,870
1,604
Human Capital
Physical Health & Longevity
3.8% shared · 9,055 families in both
United States
China
South Korea
Japan
Germany
77,497
32,383
14,190
14,101
7,671
Strategic Infrastructure
Health Infrastructure
3.5% shared · 4,064 families in both
United States
Japan
China
South Korea
Germany
24,406
13,906
7,434
6,894
5,818
Production & Innovation
Services Economy
3.4% shared · 4,084 families in both
United States
Japan
South Korea
China
Germany
24,048
16,321
11,491
8,566
3,398
Crosswalk
How Genomics & Biological Data is matched to the patent classifications. The entries below were chosen for it; each stands for itself and everything beneath it in the scheme, 80 Cooperative entries in all. A patent family counts when any of its codes, in either scheme and at any office, falls under one of them. Codes since retired are placed under the entries that replaced them.
| Entry | Title in the scheme | Why it is chosen | CPC codes | IPC codes | Documents |
|---|---|---|---|---|---|
| C12Q1/68 | Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids | Nucleic acid analysis: sequencing, amplification, probes | 42 | 41 | 1,052,217 |
| G16B | Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology | Bioinformatics and genomic data processing | 37 | 39 | 388,324 |
CPC and IPC codes are the codes in use on patent documents, at any office, that fall under the entry. Documents is the larger of the two schemes' counts of documents carrying one of them. An entry with no IPC codes can be told apart only in the Cooperative scheme.
The Cooperative codes in use that count towards Genomics & Biological Data: 79 codes on 1,440,541 documents. The full crosswalk is in the cpc-to-capability.csv download.
| Code | Title | Under entry | How placed | Documents |
|---|---|---|---|---|
| C12Q1/6886 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer | C12Q1/68 | In the scheme | 132,760 |
| C12Q1/6883 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material | C12Q1/68 | In the scheme | 109,940 |
| C12Q1/6806 | Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay | C12Q1/68 | In the scheme | 69,216 |
| C12Q1/6869 | Methods for sequencing | C12Q1/68 | In the scheme | 65,074 |
| C12Q1/686 | Polymerase chain reaction [PCR] | C12Q1/68 | In the scheme | 63,033 |
| C12Q1/6895 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae | C12Q1/68 | In the scheme | 51,715 |
| C12Q1/68 | Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids | C12Q1/68 | In the scheme | 47,613 |
| C12Q1/689 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria | C12Q1/68 | In the scheme | 45,472 |
| G16B40/00 | ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding | G16B | In the scheme | 39,203 |
| G16B20/00 | ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations | G16B | In the scheme | 37,633 |
| G16B30/00 | ICT specially adapted for sequence analysis involving nucleotides or amino acids | G16B | In the scheme | 35,092 |
| C12Q1/6844 | Nucleic acid amplification reactions | C12Q1/68 | In the scheme | 35,078 |
| C12Q1/6876 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes | C12Q1/68 | In the scheme | 34,912 |
| C12Q1/6827 | Hybridisation assays for detection of mutation or polymorphism | C12Q1/68 | In the scheme | 33,060 |
| G16B20/20 | Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection | G16B | In the scheme | 31,013 |
| C12Q1/6851 | Quantitative amplification | C12Q1/68 | In the scheme | 29,389 |
| C12Q1/6888 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms | C12Q1/68 | In the scheme | 28,489 |
| C12Q1/6858 | Allele-specific amplification | C12Q1/68 | In the scheme | 27,186 |
| C12Q1/6837 | Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips | C12Q1/68 | In the scheme | 26,884 |
| C12Q1/6816 | Hybridisation assays characterised by the detection means | C12Q1/68 | In the scheme | 24,415 |
| C12Q1/6874 | Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation | C12Q1/68 | In the scheme | 24,337 |
| G16B30/10 | Sequence alignment; Homology search | G16B | In the scheme | 24,092 |
| G16B40/20 | Supervised data analysis | G16B | In the scheme | 23,647 |
| C12Q1/6809 | Methods for determination or identification of nucleic acids involving differential detection | C12Q1/68 | In the scheme | 17,459 |
| G16B25/10 | Gene or protein expression profiling; Expression-ratio estimation or normalisation | G16B | In the scheme | 17,250 |
| G16B50/00 | ICT programming tools or database systems specially adapted for bioinformatics | G16B | In the scheme | 16,055 |
| G16B25/00 | ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression | G16B | In the scheme | 15,609 |
| G16B5/00 | ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks | G16B | In the scheme | 15,323 |
| C12Q1/6834 | Enzymatic or biochemical coupling of nucleic acids to a solid phase | C12Q1/68 | In the scheme | 14,915 |
| C12Q1/6897 | Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters | C12Q1/68 | In the scheme | 14,510 |
| C12Q1/6881 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes | C12Q1/68 | In the scheme | 14,101 |
| C12Q1/6813 | Hybridisation assays | C12Q1/68 | In the scheme | 13,288 |
| C12Q1/6825 | Nucleic acid detection involving sensors | C12Q1/68 | In the scheme | 13,034 |
| C12Q1/6804 | Nucleic acid analysis using immunogens | C12Q1/68 | In the scheme | 12,242 |
| C12Q1/6841 | In situ hybridisation | C12Q1/68 | In the scheme | 12,041 |
| C12Q1/6853 | Nucleic acid amplification reactions using modified primers or templates | C12Q1/68 | In the scheme | 11,756 |
| C12Q1/6818 | Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer | C12Q1/68 | In the scheme | 11,080 |
| C12Q1/6848 | Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction | C12Q1/68 | In the scheme | 10,609 |
| G16B15/00 | ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment | G16B | In the scheme | 10,530 |
| G16B15/30 | Drug targeting using structural data; Docking or binding prediction | G16B | In the scheme | 10,168 |
| G16B40/10 | Signal processing, e.g. from mass spectrometry [MS] or from PCR | G16B | In the scheme | 9,390 |
| G16B45/00 | ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks | G16B | In the scheme | 9,146 |
| G16B20/30 | Detection of binding sites or motifs | G16B | In the scheme | 8,839 |
| C12Q1/6811 | Selection methods for production or design of target specific oligonucleotides or binding molecules | C12Q1/68 | In the scheme | 8,156 |
| G16B50/30 | Data warehousing; Computing architectures | G16B | In the scheme | 8,083 |
| C12Q1/6855 | Ligating adaptors | C12Q1/68 | In the scheme | 7,950 |
| G16B40/30 | Unsupervised data analysis | G16B | In the scheme | 7,904 |
| G16B20/10 | Ploidy or copy number detection | G16B | In the scheme | 7,777 |
| C12Q1/682 | Signal amplification | C12Q1/68 | In the scheme | 7,627 |
| G16B20/50 | Mutagenesis | G16B | In the scheme | 6,979 |
| G16B25/20 | Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation | G16B | In the scheme | 5,978 |
| G16B30/20 | Sequence assembly | G16B | In the scheme | 5,964 |
| C12Q1/6823 | Release of bound markers | C12Q1/68 | In the scheme | 5,479 |
| C12Q1/683 | Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP] | C12Q1/68 | In the scheme | 5,406 |
| G16B20/40 | Population genetics; Linkage disequilibrium | G16B | In the scheme | 5,288 |
| C12Q1/6832 | Enhancement of hybridisation reaction | C12Q1/68 | In the scheme | 5,054 |
| G16B35/00 | ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides | G16B | In the scheme | 4,683 |
| G16B15/20 | Protein or domain folding | G16B | In the scheme | 4,372 |
| G16B5/20 | Probabilistic models | G16B | In the scheme | 4,046 |
| G16B99/00 | Subject matter not provided for in other groups of this subclass | G16B | In the scheme | 3,847 |
| C12Q1/6865 | Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS] | C12Q1/68 | In the scheme | 3,841 |
| G16B50/10 | Ontologies; Annotations | G16B | In the scheme | 3,532 |
| G16B35/20 | Screening of libraries | G16B | In the scheme | 3,309 |
| C12Q1/6846 | Common amplification features | C12Q1/68 | In the scheme | 3,200 |
| C12Q1/6893 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa | C12Q1/68 | In the scheme | 2,867 |
| C12Q1/6879 | Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination | C12Q1/68 | In the scheme | 2,750 |
| G16B10/00 | ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis | G16B | In the scheme | 2,697 |
| C12Q1/6872 | Methods for sequencing involving mass spectrometry | C12Q1/68 | In the scheme | 2,284 |
| G16B35/10 | Design of libraries | G16B | In the scheme | 2,169 |
| C12Q1/6862 | Ligase chain reaction [LCR] | C12Q1/68 | In the scheme | 2,030 |
| G16B50/20 | Heterogeneous data integration | G16B | In the scheme | 1,936 |
| G16B50/50 | Compression of genetic data | G16B | In the scheme | 1,861 |
| G16B50/40 | Encryption of genetic data | G16B | In the scheme | 1,458 |
| C12Q1/6839 | Triple helix formation or other higher order conformations in hybridisation assays | C12Q1/68 | In the scheme | 1,350 |
| G16B5/30 | Dynamic-time models | G16B | In the scheme | 1,325 |
| G16B25/30 | Microarray design | G16B | In the scheme | 850 |
| G16B15/10 | Nucleic acid folding | G16B | In the scheme | 696 |
| C12Q1/6867 | Replicase-based amplification, e.g. using Q-beta replicase | C12Q1/68 | In the scheme | 615 |
| G16B5/10 | Boolean models | G16B | In the scheme | 580 |